
ZFGN
Healthcare · Biotechnology · $3.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 8, 2020 | Time not confirmed | — | -0.10 | — |
| Mar 6, 2020 | Time not confirmed | -0.19 | -0.19 | 0.0% |
| Nov 7, 2019 | Time not confirmed | -0.27 | -0.35 | -29.6% |
| Aug 9, 2019 | Time not confirmed | -0.36 | -0.32 | +11.1% |
| May 10, 2019 | Time not confirmed | -0.42 | -0.35 | +16.7% |
| Mar 12, 2019 | Time not confirmed | -0.44 | -0.39 | +10.6% |
| Nov 8, 2018 | Time not confirmed | -0.47 | -0.41 | +12.5% |
| Aug 8, 2018 | Time not confirmed | -0.59 | -0.57 | +3.0% |
| May 9, 2018 | Time not confirmed | -0.52 | -0.58 | -11.4% |
| Mar 7, 2018 | Time not confirmed | -0.57 | -0.48 | +16.5% |
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops methionine aminopeptidase 2 inhibitors for common and rare metabolic disorders. The company was founded in 2005 and is headquartered in Boston, Massachusetts.